Michelle Renee Griffin net worth and biography

Michelle Griffin Biography and Net Worth

Michelle Griffin has served on our board of directors since March 2019. Michelle currently serves on the board of directors of Acer Therapeutics, Inc, a public company, including as chair of the audit committee. Michelle also currently serves on the board of directors of HTG Molecular Diagnostics, Inc., a public company, including as chair of the audit committee. She previously served on the board of directors and as chair of the audit committee of PhaseRx, Inc., a public company, from 2016 to 2018, OncoGenex Pharmaceuticals Inc., a Nasdaq listed company, from 2008 to 2011 and Sonus Pharmaceuticals, Inc., a public company, from 2004 to 2008. Michelle served as Executive Vice President, Operations, and Chief Financial Officer at OncoGenex Pharmaceuticals, Inc. from 2011 to 2013, served as Acting Chief Executive, Senior Vice President and Chief Operating Officer at Trubion Pharmaceuticals, Inc. from 2009 until its acquisition in 2010 and as its Chief Financial Officer from 2006 to 2009; and served as Senior Vice President and Chief Financial Officer of Dendreon Corp. from 2005 to 2006. Michelle holds a BS in marketing from George Mason University and an MBA from Seattle University.

What is Michelle Renee Griffin's net worth?: The estimated net worth of Michelle Renee Griffin is at least $396,423.95 as of March 6th, 2025. Ms. Griffin owns 51,685 shares of Adaptive Biotechnologies stock worth more than $396,424 as of March 29th. This net worth evaluation does not reflect any other assets that Ms. Griffin may own. Learn More about Michelle Renee Griffin's net worth.
How do I contact Michelle Renee Griffin?: The corporate mailing address for Ms. Griffin and other Adaptive Biotechnologies executives is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. Adaptive Biotechnologies can also be reached via phone at (206) 659-0067 and via email at investors@adaptivebiotech.com. Learn More on Michelle Renee Griffin's contact information.
Has Michelle Renee Griffin been buying or selling shares of Adaptive Biotechnologies?: During the past quarter, Michelle Renee Griffin has sold $124,372.16 in Adaptive Biotechnologies stock. Most recently, Michelle Renee Griffin sold 15,664 shares of the business's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $7.94, for a transaction totalling $124,372.16. Following the completion of the sale, the director now directly owns 51,685 shares of the company's stock, valued at $410,378.90. Learn More on Michelle Renee Griffin's trading history.
Who are Adaptive Biotechnologies' active insiders?: Adaptive Biotechnologies' insider roster includes R. Adams (COO), Lance Baldo (Insider), Sharon Benzeno (Insider), Chad Cohen (CFO), Egon Durban (Director), David Goel (Director), Michelle Griffin (Director), Robert Hershberg (Director), Francis Lo (Insider), Peter Neupert (Director), Jyoti Palaniappan (SVP), Kyle Piskel (CFO), Chad Robins (CEO), Chad Robins (CEO), Harlan Robins (Insider), Julie Rubinstein (President), and Stacy Taylor (SVP). Learn More on Adaptive Biotechnologies' active insiders.
Are insiders buying or selling shares of Adaptive Biotechnologies?: During the last twelve months, insiders at the sold shares 12 times. They sold a total of 757,849 shares worth more than $6,041,858.67. The most recent insider tranaction occured on March, 24th when insider Harlan S Robins sold 1,698 shares worth more than $15,282.00. Insiders at Adaptive Biotechnologies own 6.2% of the company. Learn More about insider trades at Adaptive Biotechnologies.
Information on this page was last updated on 3/24/2025.

Michelle Renee Griffin Insider Trading History at Adaptive Biotechnologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/6/2025	Sell	15,664	$7.94	$124,372.16	51,685
3/27/2023	Sell	2,341	$8.49	$19,875.09	20,627
8/27/2021	Sell	14,916	$35.00	$522,060.00	16,420
7/14/2021	Sell	2,500	$36.80	$92,000.00
6/17/2021	Sell	4,000	$40.00	$160,000.00	5,504
6/14/2021	Sell	2,500	$38.56	$96,400.00	4,004
5/18/2021	Sell	2,500	$35.00	$87,500.00	4,004
4/14/2021	Sell	4,500	$43.41	$195,345.00	6,004
3/15/2021	Sell	4,500	$41.75	$187,875.00	6,004
2/16/2021	Sell	6,000	$65.08	$390,480.00	1,504
1/14/2021	Sell	6,000	$65.88	$395,280.00	6,000
11/16/2020	Sell	6,000	$47.69	$286,140.00	6,000

Michelle Renee Griffin Buying and Selling Activity at Adaptive Biotechnologies

Adaptive Biotechnologies Company Overview

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Today's Range

Now: $7.67

$7.50

$8.23

50 Day Range

MA: $7.89

$6.67

$8.66

2 Week Range

Now: $7.67

$2.28

$9.01

Volume

1,563,957 shs

Average Volume

1,472,425 shs

Market Capitalization

$1.14 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53